Cingulate Stock Soars on Key ADHD Drug Patent Approval

Edgen Stock

·Mar 16 2026, 18:03

Share to

Share to

Copy link

Key Takeaways

Cingulate Inc. (NASDAQ: CING) shares experienced a significant price increase on March 16, 2026, after the U.S. Patent and Trademark Office (USPTO) approved a critical patent related to its primary drug candidate for ADHD, CTx-1301. This regulatory win solidifies the company's intellectual property and boosts investor outlook.

Patent Secured: The USPTO granted a patent for Cingulate's "Trimodal, Precision-Time Pulsatile Release Tablet" technology.
Stock Reacts: CING shares soared on March 16 as the market priced in the positive development for the company's pipeline.
Future De-Risked: The approval protects the company's lead ADHD drug candidate, CTx-1301, from competition and strengthens its position for potential partnerships or future commercialization.

USPTO Grants Cingulate Key Patent for ADHD Drug Technology

Shares of Cingulate Inc. (NASDAQ: CING) climbed sharply on Monday, March 16, 2026, after the company secured a major regulatory victory. The U.S. Patent and Trademark Office (USPTO) approved a key patent application for Cingulate's proprietary “Trimodal, Precision-Time Pulsatile Release Tablet” technology. This development was a significant catalyst for the stock, triggering a wave of positive investor sentiment.

Patent Secures Future of Lead Candidate CTx-1301

The newly granted patent is crucial as it safeguards the technology behind CTx-1301, Cingulate's leading drug candidate designed to treat Attention-Deficit/Hyperactivity Disorder (ADHD). By protecting its core intellectual property, Cingulate has significantly de-risked the asset's development path. This protection enhances the company's competitive standing and makes it more attractive for future investment and strategic partnerships as it moves toward potential commercialization, pending successful clinical trials.